Scarica l'app Stockscreener
11.30
0.62%
0.07
Dopo l'orario di chiusura:
11.30
Precedente Chiudi:
$11.23
Aprire:
$11.26
Volume 24 ore:
70,236
Relative Volume:
0.26
Capitalizzazione di mercato:
$565.02M
Reddito:
$62.02M
Utile/perdita netta:
$-45.65M
Rapporto P/E:
-12.28
EPS:
-0.92
Flusso di cassa netto:
$-9.60M
1 W Prestazione:
-3.00%
1M Prestazione:
+6.91%
6M Prestazione:
+16.86%
1 anno Prestazione:
+12.10%
Intervallo 1D:
$11.26
$11.35
Intervallo di 1 settimana:
$11.16
$11.88
Portata 52W:
$7.44
$11.88
Theravance Biopharma Inc Stock (TBPH) Company Profile
Nome
Theravance Biopharma Inc
Settore
Industria
Telefono
650-808-6000
Indirizzo
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Confronta TBPH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
11.30 | 561.51M | 62.02M | -45.65M | -9.60M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-06 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-04-12 | Iniziato | BTIG Research | Buy |
| 2024-01-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2021-11-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-09-15 | Downgrade | JP Morgan | Overweight → Underweight |
| 2021-08-25 | Downgrade | Morgan Stanley | Overweight → Underweight |
| 2021-08-24 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-10-14 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-07 | Iniziato | JP Morgan | Overweight |
| 2020-06-15 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-05-13 | Iniziato | Cowen | Outperform |
| 2020-01-08 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-06 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2019-10-29 | Iniziato | H.C. Wainwright | Buy |
| 2018-03-29 | Ripresa | Piper Jaffray | Overweight |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-06-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-05-11 | Reiterato | Needham | Buy |
| 2016-12-21 | Iniziato | Needham | Buy |
| 2016-11-03 | Iniziato | Piper Jaffray | Overweight |
| 2016-10-12 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2016-08-03 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2016-06-20 | Iniziato | Guggenheim | Buy |
| 2016-06-20 | Reiterato | Leerink Partners | Outperform |
| 2016-05-12 | Iniziato | Leerink Partners | Outperform |
| 2016-05-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2015-02-03 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
Mostra tutto
Theravance Biopharma Inc Borsa (TBPH) Ultime notizie
What analysts say about Theravance Biopharma Inc. stockExplosive trading growth - jammulinksnews.com
Theravance Biopharma Inc. Stock Analysis and ForecastExceptional trading results - Autocar Professional
Theravance Biopharma to Participate in an Upcoming Investor Conference - Citizen Tribune
Is Theravance Biopharma Inc. a good long term investmentFast-track wealth growth - jammulinksnews.com
What drives Theravance Biopharma Inc. stock priceConsistent triple-digit returns - jammulinksnews.com
How Theravance Biopharma Inc. stock performs during market volatilitySecure Your Capital Strategy - Newser
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics - The Globe and Mail
Theravance Biopharma SVP Farnum sells $113,869 in stock By Investing.com - Investing.com Nigeria
Theravance Biopharma SVP Farnum sells $113,869 in stock - Investing.com
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats - The Globe and Mail
What makes Theravance Biopharma Inc. stock price move sharplyStrategic High Profit Opportunities - Newser
Why Theravance Biopharma Inc. stock attracts strong analyst attentionFree Daily Stock Market Updates - Newser
Viatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharma - Insider Monkey
Brokerages Set Theravance Biopharma, Inc. (NASDAQ:TBPH) Target Price at $16.60 - Defense World
Theravance Biopharma SVP Sells 7,000 Shares for $78,000 on July 14, 2025. - AInvest
Theravance higher as China approves Viatris-partnered COPD therapy - MSN
Theravance Biopharma (NASDAQ:TBPH) Downgraded to “Hold” Rating by Wall Street Zen - Defense World
Theravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from Russell 2000 Defensive Index - MarketScreener
Theravance Biopharma, Inc.(NasdaqGM: TBPH) added to Russell Microcap Growth Index - MarketScreener
Theravance Biopharma (NASDAQ:TBPH) Given New $25.00 Price Target at BTIG Research - Defense World
TBPH Stock Price Target Increased Following Milestone Payment | TBPH Stock News - GuruFocus
JonesTrading Maintains Theravance Biopharma(TBPH.US) With Buy Rating, Maintains Target Price $24 - 富途牛牛
Theravance Biopharma price target raised to $25 by BTIG on China approval - Investing.com
Is Theravance Biopharma, Inc. technically bullish or bearish? - MarketsMojo
Theravance Biopharma (NASDAQ:TBPH) Now Covered by Jones Trading - Defense World
Theravance Biopharma (NASDAQ:TBPH) Stock Rating Upgraded by Jones Trading - Defense World
Theravance Biopharma (TBPH) Receives New Analyst Coverage with a Buy Rating | TBPH Stock News - GuruFocus
(TBPH) Proactive Strategies - news.stocktradersdaily.com
Theravance Biopharma (TBPH) Gains Buy Rating with Promising Drug Prospects | TBPH Stock News - GuruFocus
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 32,534 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance and Mylan settle patent dispute with Eugia Pharma - MSN
theravance biopharma settles patent litigation with eugia pharma By Investing.com - Investing.com South Africa
Theravance Biopharma Inc Azioni (TBPH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.91%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):